Hello! I’m Cristina Sebastião Matushita, a board-certified Nuclear Medicine Physician by AMB/CBR and a certified Radiation Protection Supervisor by CNEN
I just watched an incredible lecture by Michael Hofman from the Peter MacCallum Cancer Centre at SNMMI. He was awarded the prestigious Saul Hertz Prize in theranostics. Saul Hertz pioneered radioisotope therapy, asking, “Can we create radioactive iodine artificially?” His work revolutionized the field. Hofman, initially in nuclear cardiology, shifted to PET/CT with Gallium-68 tracers. Realizing the need for strong clinical trial data, he established a collaborative network in Australia, advancing nuclear medicine worldwide. His PROPSMA study showed PSMA PET/CT is 40% superior to conventional imaging for prostate cancer, leading to its inclusion in global guidelines and making it one of the top-cited papers in Lancet Oncology. He emphasized the need for high-quality clinical trials to transform nuclear medicine. The TheraP study compared Lutetium-PSMA with cabazitaxel, showing better response and fewer side effects. Hofman also highlighted the exciting potential of Terbium-161 PSMA in the Violet study. Stay tuned for some standout slides from his lecture! Society of Nuclear Medicine and Molecular Imaging (SNMMI) #NuclearMedicine #SNMMI #Theranostics #MichaelHofman #SaulHertz #ProstateCancer #PSMAPET #ClinicalTrials #MedicalImaging #LuPSMA #Terbium161